How many drugs treat Anthrax?

Drug Landscape tracks 10 marketed treatments for Anthrax (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/anthrax.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Anthrax — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anthrax (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Anthrax, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Minocycline Hydrochloride	MINOCYCLINE	Rempex	Tetracycline-class Drug		1971-01-01
Vibramycin	doxycycline	Generic (originally Pfizer)	Tetracycline antibiotic	72 kDa type IV collagenase, Stromelysin-1, Collagenase 3	1967-01-01
Abelcet	AMPHOTERICIN B	Astellas Pharma	Lipid-based Polyene Antifungal [EPC]		1964-01-01
Demethylchlortetracycline	DEMECLOCYCLINE	Pfizer	Tetracycline-class Antimicrobial	Estrogen receptor beta	1960-01-01
Penicillin G Potassium In Plastic Container	Benzylpenicillin	Pfizer	Penicillin-class Antibacterial		1947-01-01
Minocyclin	Minocyclin	University of Southern California		30S ribosomal protein S4, 30S ribosomal protein S9, Tetracycline resistance protein, class B
Meclan	MECLOCYCLINE	Johnson And Johnson	meclocycline
penicillin	penicillin	Karlstad University		Bacterial penicillin-binding protein, Beta-lactamase, Beta-lactamase TEM

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Anthrax
Pfizer · 2 drugs in Anthrax
Astellas Pharma · 1 drug in Anthrax
Bayer AG · 1 drug in Anthrax
Bulovka Hospital · 1 drug in Anthrax
Generic (originally Daiichi Sankyo/J&J) · 1 drug in Anthrax
Generic (originally Pfizer) · 1 drug in Anthrax
Johnson And Johnson · 1 drug in Anthrax
Karlstad University · 1 drug in Anthrax
Poitiers University Hospital · 1 drug in Anthrax
Rempex · 1 drug in Anthrax
University of Southern California · 1 drug in Anthrax

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Anthrax:

Cite this brief

Drug Landscape (2026). Anthrax — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/anthrax. Accessed 2026-06-10.

Anthrax full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing